)

Ionis Pharmaceuticals (IONS) investor relations material
Ionis Pharmaceuticals Innovation Day 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Strategic Vision and Growth Outlook
Focused on becoming a fully integrated, commercial-stage biotech, prioritizing wholly owned pipeline and independent launches in neurology and cardiometabolic diseases, with a steady cadence of independent and partnered medicine launches targeting both rare and prevalent diseases.
Achieved or exceeded all key milestones set six years ago, including building a robust pipeline, commercial organization, and expanding RNA-targeted drug discovery.
Advancing a high-value, innovative pipeline with multiple late-stage and recently approved medicines, including TRYNGOLZA, DAWNZERA, and Olezarsen.
Ongoing investment in technology platforms, including RNA-targeted medicines, siRNA, and delivery innovations to maintain leadership and expand therapeutic reach.
Clear path to sustained positive cash flow by 2028, supported by strong financial resources (~$2B cash), disciplined expense management, and efficient capital structure.
Key Product and Clinical Developments
TRYNGOLZA (olezarsen) approved for FCS, showing substantial triglyceride and pancreatitis reduction, strong early commercial uptake, and approved in the EU.
Olazarsen demonstrated up to 72% mean placebo-adjusted triglyceride reduction and 85% reduction in acute pancreatitis in SHTG, with sNDA filing planned by year-end and launch expected in the second half of next year.
DAWNZERA (donidalorsen) launched in the US for HAE, offering first RNA-targeted prophylactic with strong efficacy, tolerability, and convenient dosing; EU launch anticipated in 2026.
Zilganersen pivotal data for Alexander disease showed disease stabilization and robust safety, with NDA filing and first neurology launch planned for next year.
ION582 for Angelman syndrome showed positive long-term data and broad Phase III enrollment, targeting both pediatric and adult populations, with full enrollment expected in 2026.
Commercial and Financial Strategy
Commercial infrastructure built to support current and future launches, with omnichannel education reaching over 30,000 HCPs and strong payer dynamics.
FCS launch generated $19M in Q2 revenue, with full-year guidance of $75–80M; Donzara launch off to an encouraging start.
Olazarsen positioned as a potential blockbuster, targeting a million high-risk SHTG patients initially, with pricing and access strategy under development.
Financial discipline maintained, with $2B in cash, clear path to sustained positive cash flow by 2028, and peak annual revenue potential exceeding $5B from multiple products and royalties.
Multiple blockbuster opportunities in the pipeline, with independent and partner launches expected to generate over $5B in combined annual peak revenue.
Next Ionis Pharmaceuticals earnings date

Next Ionis Pharmaceuticals earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage